Allurion Technologies treats first commercial patients in the U.S.

Allurion Technologies (ALUR) announced the commercial treatment of its first patients in the United States-an inflection point that formally launches the company into the world’s largest and most dynamic obesity market. Allurion is seeing growing demand from patients who have discontinued GLP-1 therapy due to side effects, long-term commitment concerns, or weight regain following discontinuation. These early patient profiles reinforce Allurion’s positioning as a compelling, non-surgical, non-pharmaceutical option that delivers fast weight loss results within the rapidly evolving obesity treatment landscape. Early feedback from trained centers has been highly encouraging, underscoring the differentiated value of the Allurion Program, especially among patients who are searching for alternatives to GLP-1 medications. Clinicians have highlighted the Program’s simplicity and scalability as a competitive advantage, with the entire placement taking only about 15 minutes and requiring no endoscopy or anesthesia. In addition to its growing network of clinical partners, Allurion also announced that it is actively exploring partnerships with self-insured employers. These initiatives aim to substantially expand the pool of patients who can access the Allurion Smart Capsule through employer-sponsored coverage, while helping employers address the rising health and productivity costs associated with obesity.